ESR1 and neoplasm: In contrast, ERβ suppresses the proliferation of tumor cells.4,5 The carcinogenic effect of E2 via ERα has been highlighted by experiments in ER-knockout mice6 and by epidemiological studies on cancer risk in patients who receive female hormone replacement therapy, showing an increased risk to develop breast, gynecologic and endocrine gland cancers.